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D ESP IT E IN TEN S IV E IN V ES TIG
A TIO N , much remains to be learned about the sequence of events leading to development of the acquired immunodeficiency virus syndrome (AIDS) following human immunodeficie ncy virus (HIV) infection. Of utmost importance is an understanding of how HIV gene expression is controlled during the viral life cycle. In this regard, the long terminal repeats (LTRs), present at either end of the HIV genome, contain the essential cis-acting signals that specify the start site for RNA transcription and modulate the amounts of HIV RNA synthesized. 1,2 HIV replication is critically dependent on two viral regulatory proteins, Tat and Rev, 3 and Tat is required early in the viral life cycle to increase the rate of transcription from the viral LTR. 3 Growth hormone (GH) and insulin-like growth factor I (IGF-I) have been shown to affect functional immune status 4±6 and lean body mass. 7±12 In addition, our laboratory has demonstrated that IGF-I can inhibit HIV replication. 1 3 Regarding this latter effect of IGF-I on HIV replication, the mechanism has not been elucidated. 13 In our continuing efforts to understand this IGF-I-induced inhibition of HIV replication, we report herein that IGF-I inhibition of HIV replication is related to IGF-I inhibition of LTR-directed gene expression. Using an HIV LTR chloramphenico l acetyltransferase (CAT) reporter (HIVLTRCAT), we show that IGF-I inhibited Tat-m ediated HIVLTRCAT expression while having little effect on basal (i.e., in the absence of Tat) CAT production. Other factors that have known inhibitory sites regarding CAT expression have been studied in combination with IGF-I to uncover the inhibitory site(s) for this hormone. We also show that IGF-I can inhibit production of infectious HIV virions when COS 7 cells are transfected with complete genomic proviral DNA. Further, we have found that CAT expression is inhibited by IGF-I in traditional target cell lines (e.g., Jurkat cells, a T cell line, and U937 cells, a promonocytic cell line) transfected with HIVLTRCAT/tat.
M ATERIALS AND M ETH ODS

Cell culture
The cells employed in our transfection studies were COS 7 cells, Jurkat cells, and U937 cells. COS 
Materials
Functional studies of the HIV promoter have been conducted primarily through experiments in which the HIV LTR has been linked to a reporter gene, i.e., the bacterial cat gene.
14 An HIVLTRCAT construct and a pSV tat construct were kindly provided by J. Hiscott (Lady Davis Institute, Montreal, Quebec, Canada). IGF-I was kindly supplied by Genentech (San Francisco, CA).
Transfections
For COS 7 transfections, a standard calcium phosphate precipitation procedure was employed. 1 4a In short, COS 7 cells were plated in 10% (v/v) DMEM to yield approximately 30% confluence after 24 hr. At this time, the medium was changed to 1% (v/v) DMEM and incubated for 2 hr at 37°C. DNA was adjusted to 15 m g/plate with calf thymus DNA prepared in deionized water and 0.25 M CaCl 2 in a volume of 0.5 ml. Air was bubbled into 0.5 ml of 23 HEPES buffer (280 mM NaCl, 50 mM HEPES, and 1.5 mM Na 2 HPO 4 ? 7H 2 O) while simultaneously, slowly dripping the DNA mixture into the HEPES solution. Bubbling was continued until the solution was slightly cloudy due to CaPO 4 ±DNA precipitation. After allowing the solution to sit at room temperature to achieve maximum precipitation, the DNA±HEPES solution was added to the plates and incubated at 37°C for 4 hr. At this time, the plates were washed twice with phosphate-buffered saline (PBS) (Ca 21 /Mg 21 free) and treated as required. For Jurkat cells, the DEAE-dextran method was employed. 15 Briefly, 6 3 10 
CAT analysis
At varying times following transection, cells were harvested and washed in 4°C PBS. Cells were then washed in TEN buffer (40 mM Tris [pH 7.5], 1 mM EDTA [pH 8.0], 15 nM NaCl). Cell lysates (i.e., the supernatants) were collected and analyzed for [1,2- 14 C]chloramphenicol (ICN, Costa Mesa, CA) metabolites. The samples were extracted with ethyl acetate spotted on thin-layer chromatography (TLC) silica gel membranes (Whatman, Clifton, NJ) and run with a chloroform±methanol (95:5) eluant. TLC autoradiograms were produced from the TLC membranes following exposure to autoradiography film (Du Pont, Wilmington, DE). When possible, all CAT assays with low (, 1%) or high (. 70%) acetylation were repeated with more or less extract. The amount of protein and time of incubation at 37°C were adjusted for degree of acetylation. Quantitation of different acetylated metabolites of [ 14 C]chloramphenicol was done using phosphorimage analysis of the patterns produced after the TLC was exposed to a Bio-Rad GS 250 screen BI for varying amounts of time and visualized using the Bio-Rad GS-363 Molecular Imager system. Analysis was performed using Bio-Rad Molecular Analyst software (version 2.0.1).
Reverse transcriptase assay
Reverse transcriptase assays were carried out by a modification of a previously published procedure. 3 ,16 
Detection of p24 antigen by enzyme immunoassay
Virus production was monitored by detection of p24 core antigen in cell-free culture supernatants, using an enzyme immunoassay (EIA) diagnostic kit (Abbott Laboratories, Mississauga, Ontario, Canada).
Statistics
The statistical analyses employed herein include the twotailed t test and one-way analysis of variance (ANOVA). The lowest level of significance was set at p , 0.05.
RESU LTS
An initial series of experiments was performed that reconfirm ed that exposure to IGF-I caused a significant decrease in culture medium reverse transcriptase (RT) activity produced by chronically HIV-1-infected U937 cells (i.e., with the laboratory strain HIV-IIIB) (Fig. 1) . Nearly 40% inhibition of medium RT activity was seen after 24 hr of exposure to IGF-I (100 ng/ml) (p , 0.05, one-way ANOVA, n 5 4). Further, the 40% inhibition of HIV replication by IGF-I was abrogated by a -IR3, a specific antibody to the IGF-I receptor. 17 In addition, an anti-IGF-I antibody blocked the IGF-I effect on HIV replication (data not shown).
To gain some insight into the mechanism of action of IGF-I on HIV replication, COS 7 cells were cotransfected for 4 hr with HIVLTRCAT/tat (1 m g of each plasmid per milliliter) made up to 10 m g/ml with carrier calf thymus DNA. After the calcium phosphate±DNA mixture was rem oved, the cells were treated with IGF-I in DMEM containing 1% (v/v) fetal calf The percent inhibition is plotted versus treatment and was quantitated by phosphoimage analysis of the spots generated. The colum ns represent an average of the two spots aligned directly above. Liquid scintillation counting of the spots produced identical patterns when compared with the phosphoimage patterns. Data are presented as means 6 SEM.
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serum. After 48 hr, the monolayers were extracted and CAT activity was determined. The data in Fig. 2A and B demonstrate a concentration-dep endent inhibition of CAT activity by IGF-I (77% inhibition at 10 ng/ml [1.3 nM] and 94% inhibition at 50 ng/ml [6.5 nM] IGF-I). A modest 29% inhibition of CAT expression by a pharmacologic amount (i.e., 500 mU/ml) of insulin has been seen (data not shown). In an earlier study, 13 we demonstrated that physiological concentrations of IGF-I 18 (i.e., 50±100 ng/ml) could inhibit HIV-1 replication in cord blood mononuclear cells and chronically infected U937 cells. In this study, we have shown that COS 7 cells cotransfected with the HIV LTR linked to a cat reporter and tat express high levels of CAT and that physiologic concentrations 18 of IGF-I significantly inhibit CAT expression (Fig. 3) .
To determine if the effect of IGF-I was specific for the HIV LTR prom oter, we tested the effect of IGF-I on CAT activity in COS 7 cells transfected with a pSVCAT construct. In Table  1 , it can be seen that IGF-I had little effect on CAT activity (i.e., 100 ng of IGF-I per milliliter resulted in an average CAT activity of 105%) derived from cells transfected with pSV-CAT (p . 0.05, n 5 4). CAT expression, how ever, in HIVL-TRCAT/tat-transfec ted cells, was inhibited 48% at 50 ng of IGF-I per milliliter (p , 0.05, n 5 4). The differences seen in the levels of inhibition of CAT expression ( Fig. 2 versus Table  1 ) represent the inherent variability norm ally seen in both biological and transfection studies. Further, transfection with HIVLTRCAT but no tat resulted in considerabl y reduced CAT expression (, 7% of HIVLTRCAT/tat expression) that was not affected by IGF-I (p . 0.05, n 5 4). Also, we have not seen any effect of IGF-I on another prom oter, using COS 7 cells transfected with a plasm id containing a phosphogly cerate kinase prom oter linked to a luciferase reporter (data not show n). In Fig. 4 , it can be seen that the effect of IGF-I on CAT activity was time dependent, demonstra ting a maxim al effect (, 48% inhibition) by 48±72 hr and decreasing by 96 hr to no inhibition. In this latter type of experiment , the IGF-I concentrati on employed was 100 ng/ml but no additional IGF-I was added during the course of the experimen t. Therefore, it is likely that the IGF-I in the medium has been depleted after 4 days into the experim ent. Based on 6-hr halflife of IGF-I in the medium , less than 0.02 ng of IGF-I per milliliter would be left in the medium after 72 hr. In fact, data obtained when adding fresh IGF-I daily during the experim ent show s that the inhibitory effect is maintained for more than 4 days (data not shown).
Transfection of COS 7 cells with a plasmid containing the complete HIV proviral DNA (strain BH10), followed by the addition of IGF-I (50 ng/ml), resulted in 35% inhibition of infectious viral particle production ( Table 2 ; p , 0.001, n 5 4). This is suggestive of IGF-I inhibiting HIV replication postintegration (i.e., provirus activation).
To characterize further this effect of IGF-I on HIV LTR-driven CAT expression, we employed the Roche Tat inhibitor Ro24-7429 19 alone and in combination with IGF-I ( Table 3 ). The data in Table 3 show that the inhibition of CAT expression by IGF-I alone was , 40%, while the inhibition seen with Ro24-7429 at 10 2 8 and 10 2 7 M was 55 and 63%, respectively. IGF-I, in combination with 10 2 8 or 10 2 7 M Ro24-7429, inhibited CAT expression 57 and 55%, respectively. Since Ro24-7429 is a specific Tat inhibitor 19 and there was no additive effect of the two inhibitors, it would suggest that IGF-I might affect the Tat±TAR (trans-activation response elem ent) complex interaction or Tat interactions with other proteins. Tumor necrosis factor a (10 ng/ml), which can enhance CAT expression, was not affected by IGF-I in this transfection system (data not shown). A parathyroid hormone-related peptide (PTHRP) plasm id, minus the signaling sequence, has been reported to share similarities with the nuclear localization signal of Tat. 20 Therefore, we questioned whether PTHRP might affect Tat activation of HIVLTRCAT by competing with Tat for nuclear entry, and whether PTHRP could affect the inhibition of CAT expression by IGF-I. This latter finding might indicate a site for IGF-I-induced inhibition (i.e., competition at the level of nuclear entry). The data in Table 4 indicate that PTHRP yielded 27% inhibition of CAT plus Tat expression when compared with controls (i.e., CAT plus Tat with no PTHRP). IGF-I resulted in a 60% decrease in CAT plus Tat expression. In combination, PTHRP and IGF-I inhibited CAT expression 88% . This indicated an additivity of effects that would suggest that IGF-I is not inhibiting CAT expression at the level of Tat nuclear localization.
The observation that IGF-I can inhibit CAT expression and HIV replication in COS 7 cells, a nontarget cell for HIV, led us to investigate the effect of IGF-I in a T cell line (Jurkat) and in the promonocytic cell line U937. Cotransfection of Jurkat cells with HIVLTRCAT/tat, and subsequent exposure to IGF-I (50 ng/ml), resulted in a significant inhibition of CAT expression, i.e., 63% (Table 5 ) (p , 0.05, n 5 10). In experiments employing a Jurkat cell line stably transfected with tat, CAT expression posttransfection with HIVLTRCAT was inhibited 32% by IGF-I (data not shown). Similarly, the effect of IGF-I on CAT expression in cotransfected U937 cells (Table 5) yielded a significant (i.e., 58%) inhibition of CAT expression (p , 0.05, one-way ANOVA, n 5 7). Of considerable interest is the fact that interleukin 4 (IL-4), the signaling pathway of which is similar to that of IGF-I (i.e., via IRS-1 and IRS-2), 21±24 also significantly inhibited CAT expression (p , 0.05, one-way ANOVA, n 5 7). Further, the combination of IGF-I and IL-4 showed no significant additive inhibition (e.g., IGF-I versus IL-4 plus IGF-I; IL-4 versus IGF-I plus IL-4; p . 0.05). The preceding inform ation supports the thesis that common pathways are employed by both factors to inhibit HIVLTRCAT expression. The cell lines employed in this study all possessed IGF-I
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TA BL E 1. (Table 6 ). COS 7 and U937 cells both had significantly higher IGF-I binding than did Jurkat cells (p , 0.01, one-way ANOVA: COS 7, n 5 12; Jurkat, n 5 16; U937, n 5 6).
DISC USSION
In this article, we have demonstrated clearly that IGF-I can inhibit the functioning of the HIV LTR. Using a CAT-linked reporter, we show that Tat-amplified HIVLTRCAT expression is significantly inhibited in a concentration-and time-dependent manner by physiological levels of IGF-I 18 ( Fig. 2A and B ; and Fig. 3 ). In addition, IGF-I did not affect the expression of a pSVCAT-linked reporter at concentrations that affected HIVLTRCAT expression (Table 1 ). This effect of IGF-I was seen on the production of infectious virions by COS 7 cells transfected with proviral HIV DNA (Table 2) , which is suggestive of IGF-I inhibiting HIV at a postintegration step. As a further attempt to localize the site(s) of IGF-I inhibition, we investigated the importance of Tat in this IGF-I inhibitory effect. Data obtained on the effect of IGF-I on CAT expression in the absence of Tat amplification indicated that basal CAT expression in COS 7 cells was not affected by IGF-I (Table 1) . Our data with the specific Tat inhibitor Ro24-7429 19 and IGF-I indicated that similar inhibitory paths are involved. On the other hand, expression from a transfected plasmid of PTHRP, which has a nuclear localization signal sim ilar to that of Tat, 20 showed inhibition that was additive to that obtained with IGF-I alone (Table 4 ). This would suggest that different inhibitory paths were being employed.
The possibility that IGF-I can possibly interact with the Tat±TAR complex or some protein affecting this complex is not difficult to accept. Tat does not act alone. In addition to binding the trans-action response element (TAR), Tat must interact directly or indirectly with the transcription apparatus. Several reports have indicated a role for upstream enhancers in HIVLTRCAT/tat/PTHRP 1 IGF-I (50 ng/ml) 41,634 6 5,035 b a All conditions as in Materials and Methods. Briefly, COS 7 cells were transfected for 4 hr with HIVLTRCAT, tat, and/or PTHRP. IGF-I was added after 4 hr and CAT activity was determined after 48 hr. Quantitation was by phosphoimage analysis. Metabolic conversion of chloramphenicol to its respective metabolites ranged from 3 to 64% . All data are presented as means 6 SEM (n 5 2).
b Significantly different from HIVLTRCAT/tat: p , 0.05, one-way ANOVA.
Tat trans-activation. 25±27 The HIV LTR contains an enhancer region consisting of NF-k B and three Sp1-binding sites, 26 ,27 although a fourth Sp1 site has been identified. 28 Interestingly, different enhancer elements have different efficiencies in conferring Tat responsiveness, with Sp1 sites being most effective. 25, 29 This is to be noted since the pSVCAT construct contains an Sp1 site and is not affected by IGF-I (Table 1) . This does not necessarily exclude the involvement of the Sp1 sites in the HIV LTR for several reasons: (1) the Sp1 sites in the HIV LTR are not functionally equivalent; 30 (2) the architecture of the Sp1 site in the pSVCAT construct is physically different from that in the HIVLTRCAT construct; and (3) LTRs show different effects with respect to enhancer activation, depending on the cell type and differentiation state of the cell. 31, 32 This could relate to the number of host cell factors that are involved in Tat-m ediated effects, e.g., it has been reported that human chromosome 12 encodes a factor that can potentiate Tat transactivation in rodent cells. 33 Further, a num ber of candidate cellular proteins may play a role in Tat trans-activation. 2 All this notwithstanding , one report has demonstrated that IGF-I can disrupt Sp1 binding of the elastin gene in smooth muscle cells, possibly through the modulation of the phosphorylation state of the retinoblastom a gene product, RB. 34 How the preceding relates to the mechanism of Tat-mediated trans-activation, if at all, supports the notion that the Tat±TAR interaction is complex and controversial.
Few studies have investigated the effects of growth hormone and/or IGF-I 35 and insulin on HIV replication and HIV LTRdirected gene expression. 3 In the first study, no effect of growth hormone on HIV replication was observed, most likely owing to undetectable amounts of IGF-I produced (M.E. Geffner, personal com munication, 1997). In the second study, the investigators used micromolar amounts of insulin, which represents supraphysiologic concentrations that are not relevant in vivo. 36 Further, no mention was made as to whether the results obtained were corrected for protein content of the cell extract or whether corrections were made for transfection efficiency. In addition, the conditions employed differed considerably from those used in this study. Finally, one report 37 indicated that their data did not reliably dem onstrate IGF-I inhibition of HIV replication. 13 In their study, similar protocols were employed; however, the conditions of infection, such as the multiplicity of infection, virus preparations employed, infection procedures used, and source of IGF-I, may be related to this apparent discrepancy. However, our CAT expression data on the HIV LTR, reported herein, support the observation that was made initially by our laboratory, 13 showing that IGF-I inhibits HIV-1 replication.
Of considerable interest regarding the effect of IGF-I on HIVLTRCAT expression is that these IGF-I inhibitory effects have been observed in traditional target cell lines such as Jurkat and U937. These effects of IGF-I were seen at physiological concentrations of IGF-I 18 and further support the thesis that this molecule is relevant in HIV replication. Also, we have seen that IL-4 can inhibit HIVLTRCAT expression (Table 5) in transfected U937 cells. This inhibition by IGF-I and IL-4 was not additive (Table 5) . We believe that these effects in target cell types reflect the ability of IGF-I and IL-4 to share comm on intracellular signaling pathways. 23, 24 In an earlier report, we had hypothesized that IGF-I might be affecting HIV replication via the IL-4 pathway. 13 Since the main signal transducer for IL-4 is IRS-2, which is a major signal transducer for insulin/IGF-I, 21, 24 IGF-I may affect the IRS-2 pathway and eventually HIV LTR-driven gene expression. This should be fertile ground for future investigation. 
IG F-I IN H IBITIO N O F H IV LTR G ENE EXPRESSIO N 835
